Spots Global Cancer Trial Database for A Study of SEA-CD40 Given With Other Drugs in Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SEA-CD40 Given With Other Drugs in Cancers
Official Title: An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Study ID: NCT04993677
Study Description
Brief Summary: This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participants have melanoma that has come back after treatment or can't be removed by surgery. Participants in this part will get SEA-CD40 and pembrolizumab. In the other part, participants have non-small cell lung cancer (NSCLC) that has spread through their body. These participants will get SEA-CD40, pembrolizumab, carboplatin, and pemetrexed.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group, Springdale, Arkansas, United States
The Angeles Clinic and Research Institute, Los Angeles, California, United States
California Pacific Medical Center Research Institute/Sutter Medical Centre, San Francisco, California, United States
University of California at San Francisco, San Francisco, California, United States
Florida Cancer Specialists - South Region, Fort Myers, Florida, United States
Florida Cancer Specialists - North Region, Saint Petersburg, Florida, United States
University Cancer & Blood Center, LLC, Athens, Georgia, United States
Rush University Medical Center, Chicago, Illinois, United States
Community Health Network, Indianapolis, Indiana, United States
American Oncology Networks LLC, Baton Rouge, Louisiana, United States
Allina Health Cancer Institute, Minneapolis, Minnesota, United States
University of Minnesota, Minneapolis, Minnesota, United States
Regions Cancer Care Center, Saint Paul, Minnesota, United States
Morristown Medical Center/ Carol G. Simon Cancer Center, Morristown, New Jersey, United States
Duke University Medical Center, Durham, North Carolina, United States
Gabrail Cancer Center Research, LLC, Canton, Ohio, United States
Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States
Kaiser Permanente Oregon, Portland, Oregon, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States
University of Texas Southwestern/Simmons Cancer Center, Dallas, Texas, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States
CHU de Quebec-Universite Laval, Quebec, , Canada
Hopital Foch, Suresnes, Other, France
Universitatsklinikum Heidelberg, Heidelberg, Other, Germany
START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Other, Spain
Hospital Clinico Universitario de Valencia, Valencia, Other, Spain
Karolinska University Hospital, Stockholm, Other, Sweden
Contact Details
Name: Jonathan Hayman, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
